Transformation Agenda

To counter the revenue slide, Novo launched an oral Wegovy pill that has attracted more than 170 k U.S. patients and announced a share‑buyback up to DKK 15 bn. Management changes—including the appointment of Jamey Millar to lead the U.S. business and restructuring of U.S. product‑strategy teams—support a transformation agenda that stresses cost discipline and pipeline advancement. The 2025 annual report (Form 20‑F) confirms operations in 80 countries, marketing in approximately 170, and a workforce of 68 800. Report figures show revenue DKK 315,603.0 and net income DKK 103,773.0, underscoring a solid balance sheet, strong free cash flow and a robust capital‑return program.